ADC Therapeutics SA ROE 2019-2022 | ADCT
Current and historical return on equity (ROE) values for ADC Therapeutics SA (ADCT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| ADC Therapeutics SA ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-12-31 |
$-0.16B |
$0.09B |
-132.20% |
| 2022-09-30 |
$-0.17B |
$0.11B |
-120.95% |
| 2022-06-30 |
$-0.19B |
$0.12B |
-118.54% |
| 2022-03-31 |
$-0.20B |
$0.16B |
-103.16% |
| 2021-12-31 |
$-0.23B |
$0.17B |
-103.24% |
| 2021-09-30 |
$-0.25B |
$0.19B |
-95.02% |
| 2021-06-30 |
$-0.20B |
$0.24B |
-64.11% |
| 2021-03-31 |
$-0.26B |
$0.30B |
-84.58% |
| 2020-12-31 |
$-0.25B |
$0.34B |
-108.37% |
| 2020-06-30 |
$-0.20B |
$0.20B |
-410.20% |
| 2020-03-31 |
$-0.10B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.153B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
